Fate Therapeutics Announces New Employee Inducement Award

The clinical-stage biotech company granted restricted stock units to a newly hired non-executive employee.

Apr. 2, 2026 at 8:05pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a stack of polished glass and metal medical vials or syringes, arranged elegantly on a clean, monochromatic background and dramatically lit to symbolize the abstract concepts of biotech innovation and pharmaceutical development.Fate Therapeutics' new employee inducement award signals the biotech firm's continued growth and investment in its innovative cell therapy pipeline.San Diego Today

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced that it has granted restricted stock units (RSUs) representing 7,260 shares of its common stock to a newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company.

Why it matters

The announcement of new employee inducement awards provides insight into Fate Therapeutics' efforts to expand its workforce and build out its team as it continues to advance its pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases.

The details

The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date.

  • The grant was made on April 1, 2026.

The players

Fate Therapeutics, Inc.

A clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases.

Ryan Douglas

An employee at Fate Therapeutics, Inc. who handles investor relations.

Got photos? Submit your photos here. ›

What they’re saying

“This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site.”

— Barchart, Disclosure Policy

The takeaway

Fate Therapeutics' announcement of a new employee inducement award highlights the company's continued efforts to build out its team and advance its pipeline of innovative cellular immunotherapies, which could have important implications for the future of cancer and autoimmune disease treatment.